Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
CR Rausch, CD DiNardo, A Maiti, NJ Jammal… - Cancer, 2021 - Wiley Online Library
Background Venetoclax (VEN) combined with the hypomethylating agent (HMA) azacitidine
improves survival in patients aged≥ 75 years with newly diagnosed acute myeloid leukemia …
improves survival in patients aged≥ 75 years with newly diagnosed acute myeloid leukemia …
[HTML][HTML] BCL-2 expression in AML patients over 65 years: impact on outcomes across different therapeutic strategies
M Tiribelli, A Michelutti, M Cavallin, S Di Giusto… - Journal of Clinical …, 2021 - mdpi.com
BCL-2 overexpression has been associated with resistance to chemotherapy and reduced
survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a …
survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a …
Insights into the pathobiology of secondary AML
T Jain, RK Rampal - Acute Leukemias, 2021 - Springer
Secondary acute myeloid leukemia (s-AML) is recognized as AML arising from prior
hematological disease, usually myelodysplastic syndrome, myeloproliferative neoplasm, or …
hematological disease, usually myelodysplastic syndrome, myeloproliferative neoplasm, or …